Welcome to our dedicated page for Nucana SEC filings (Ticker: NCNA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The NuCana plc (NCNA) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as a foreign private issuer listed on The Nasdaq Capital Market. NuCana files annual reports on Form 20-F and frequent Form 6-K current reports under the Securities Exchange Act of 1934, which together give investors detailed insight into its clinical-stage oncology business, financial position, and capital markets activity.
Through these filings, NuCana reports unaudited condensed consolidated financial statements, management’s discussion and analysis of financial condition and results of operations, and information on equity financings, warrant issuances and cancellations, and at-the-market offering activity. Form 6-K submissions also include press releases on quarterly financial results, clinical data for NUC-7738 and NUC-3373, Nasdaq listing matters, ADS ratio changes, and corporate governance updates such as leadership transitions and board resignations.
For investors analyzing NuCana’s cancer drug development programs, the filings complement press releases by documenting how clinical progress, such as the NuTide:701 and NuTide:303 studies, is reflected in research and development spending, cash resources, and risk disclosures. While NuCana’s filings do not include U.S. domestic forms like 10-K or 10-Q, the Form 20-F and associated 6-K exhibits serve similar roles in outlining key risks, forward-looking statements, and the company’s dependence on external capital to fund operations.
On Stock Titan, these SEC documents are updated as they are filed with EDGAR and can be paired with AI-powered summaries that highlight important sections, such as liquidity discussions, changes in capital structure, and descriptions of clinical milestones. Users can quickly locate specific 6-K reports tied to financial results, Nasdaq compliance updates, patent announcements, or other material events, and review how NuCana describes its ProTide technology, oncology pipeline, and anticipated cash runway within its official regulatory communications.
NuCana plc Chief Executive Officer Hugh S. Griffith filed a Schedule 13D reporting beneficial ownership of 2,829,961,890 ordinary shares, equal to 12.0% of NuCana’s 20,809,854,947 ordinary shares outstanding as of March 18, 2026.
The holding includes 1,000,000 ordinary shares, 265,026 ordinary shares in the form of ADSs, and vested options to purchase 2,828,696,864 ordinary shares granted under the company’s equity plans. Griffith states the securities were acquired for investment, with no current plans for corporate actions described in Item 4, though he may change his intentions.
The filing notes it was submitted after the Section 13(d) deadline, attributing the delay to inadvertent administrative oversight and Griffith’s surgery and treatment for serious illness, and states he did not seek or believe he obtained any advantage from the late submission.
NuCana plc filed an initial statement of beneficial ownership for officer Ian Alexander Webster, outlining multiple option grants over its Ordinary Shares. These options carry exercise prices of 0.004 Pounds Sterling or 0.0004 Pounds Sterling, with varying vesting and expiration schedules.
Some option grants over Ordinary Shares completed vesting on June 20, 2025 and January 14, 2026, and expire on June 20, 2035 and January 14, 2036, respectively. Other grants begin vesting 25% on June 20, 2026 and January 14, 2027, with the remainder vesting in three equal annual installments, subject to continued service. The filing reports holdings only, with no buy or sell transactions.
NuCana plc director Kay Andrew Martin has filed an initial Form 3 disclosing significant option holdings over the company’s ordinary shares. The filing reports multiple option awards that together are exercisable into up to 63,648,062 and 52,934,010 Ordinary Shares at very low exercise prices.
According to the footnotes, some options have exercise prices between 0.0004 and 0.004 Pounds Sterling per Ordinary Share, with portions that completed vesting on June 20, 2025 and January 14, 2026 and expirations on June 20, 2035 and January 14, 2036. Other grants will vest in full on June 20, 2026 and January 14, 2027, subject to Martin’s continued service with NuCana through those vesting dates.
NuCana plc director Cyrille Leperlier reports existing stock option holdings over the company’s ordinary shares. The options are structured in four grants, each referencing ordinary shares with very low exercise prices between 0.0004 and 0.004 Pounds Sterling per share.
According to the terms, some grants are already fully vested and expire on June 20, 2035 and January 14, 2036. Other grants will vest in full on June 20, 2026 and January 14, 2027, provided Leperlier continues to serve with NuCana through those vesting dates.
NuCana plc Chief Operating Officer Theresa Margaret Bruce reported existing holdings of stock options over the company’s Ordinary Shares. One option grant over Ordinary Shares has an exercise price of 0.004 Pounds Sterling, fully vested on June 20, 2025, and expires on June 20, 2035. A second option grant over Ordinary Shares has an exercise price of 0.0004 Pounds Sterling and will vest 25% on June 20, 2026, with the remaining portions vesting in three equal annual installments, subject to her continued service with the company.
NuCana plc reports that Hugh S. Griffith has returned to his role as Chief Executive Officer and principal executive officer, effective December 15, 2025.
During his health-related leave, Executive Chairman Andrew Kay had been acting as the company’s principal executive officer; upon Mr. Griffith’s return, Mr. Kay resumed his prior position as Chairman of the Board. The update is also stated to be incorporated by reference into NuCana’s existing shelf and equity compensation registration statements on Form F-3 and Form S-8.
NuCana plc furnished a Form 6-K noting it issued a press release announcing third quarter 2025 financial results and provided accompanying materials. The filing includes unaudited condensed consolidated financial statements as of September 30, 2025 (Exhibit 99.1), Management’s Discussion and Analysis for the three and nine months ended September 30, 2025 and 2024 (Exhibit 99.2), and the November 13, 2025 press release (Exhibit 99.3).
Exhibits 99.1 and 99.2 are incorporated by reference into the Company’s registration statements on Form F-3 (File No. 333-281576) and Form S-8 (File Nos. 333-223476 and 333-248135). Exhibit 99.3 is being furnished and is not deemed filed. The Company also disclosed that, effective October 21, 2025, Bali Muralidhar, M.D., Ph.D. resigned from the Board and all committees; the resignation was not the result of any dispute regarding operations, policies, or practices.
NuCana plc (NCNA) reported that the China National Intellectual Property Administration issued a new patent covering NUC‑7738’s composition of matter. The update was communicated via a press release attached as Exhibit 99.1.
The information is incorporated by reference into the company’s registration statements on Form F‑3 (File No. 333-281576) and Form S‑8 (File Nos. 333-223476, 333-248135). The press release is being furnished, not filed, under the Exchange Act.
NuCana plc furnished a Form 6-K announcing it issued a press release about new research presented at ESMO 2025. The presentation covers a model system investigating the synergistic effects of NUC-7738 and PD-1 inhibition in primary organoids derived from patients with renal cell carcinoma.
The press release is attached as Exhibit 99.1 and is incorporated by reference. The information in Exhibit 99.1 is being furnished and not deemed filed under the Exchange Act.
NuCana plc reported an update via Form 6-K, stating that on October 14, 2025 it announced the publication of new data from the NuTide:303 clinical study evaluating NUC-3373 on medRxiv, alongside complementary preclinical findings published in the peer‑reviewed journal PLOS ONE.
The company furnished a press release as Exhibit 99.1. The information is being furnished, not filed, under the Exchange Act and is not subject to Section 18 liabilities, nor incorporated into other filings except by specific reference.